Malika Singh, MD
Endocrinology · Mission Hills, CANPI 1386878445
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 41 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 16 manufacturers reported payments, led by Novo Nordisk at 30.9% of the total. Reporting peaked in 2019 at $391 and has fallen 59.2% since, to $160 in 2025.
Across 41 payments — averaging $23.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$295
- Medtronic$147
- Ascensia Diabetes Care US Inc.$83
- Companion Medical, Inc.$59
- Abbott$55
- Pfizer$54
- plus $263 from 10 others
What the payments were for
- Food & beverage$956100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 17 | $295 |
| Medtronic | 3 | $147 |
| Ascensia Diabetes Care US Inc. | 1 | $83 |
| Companion Medical, Inc. | 1 | $59 |
| Abbott | 2 | $55 |
| Pfizer | 4 | $54 |
| Insulet Corporation | 2 | $50 |
| Bristol Myers Squibb | 2 | $40 |
| Sanofi-aventis U.S. LLC | 2 | $37 |
| Lilly USA, LLC | 1 | $24 |
| AstraZeneca | 1 | $23 |
| Dexcom, Inc. | 1 | $22 |
| Amgen | 1 | $20 |
| Merck | 1 | $19 |
| Mannkind Corporation | 1 | $16 |
| Genentech USA, Inc. | 1 | $12 |
How this compares
$956 in reported general payments places this provider in the 75th percentile of 58 endocrinology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 145 | $182,819 |
| MounjaroTirzepatide | 125 | $167,221 |
| TrulicityDulaglutide | 135 | $164,827 |
| JardianceEmpagliflozin | 136 | $145,427 |
| JanuviaSitagliptin Phosphate | 44 | $51,226 |
| Tresiba Flextouch U-200Insulin Degludec | 23 | $50,886 |
| Soliqua 100-33Insulin Glargine/Lixisenatide | 23 | $21,628 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 20 | $17,790 |
| FarxigaDapagliflozin Propanediol | 19 | $16,872 |
| Humalog Kwikpen U-100Insulin Lispro | 52 | $13,178 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 121 | $12,901 |
| TradjentaLinagliptin | 17 | $12,353 |
| Tresiba Flextouch U-100Insulin Degludec | 19 | $11,164 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 87 | $9,957 |
| Novolog FlexpenInsulin Aspart | 36 | $8,660 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Lilly USA, LLCMounjaro, Trulicity, Humalog | $24 | $337,321278 claims |
| Novo NordiskOzempic, Novolog | $295 | $187,917162 claims |
| MerckJanuvia | $19 | $51,22644 claims |
| Sanofi-aventis U.S. LLCSoliqua 100-33 | $37 | $21,62823 claims |
| AstraZenecaFarxiga | $23 | $16,87219 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 58 endocrinology providers in California.
Other endocrinology in Mission Hills
- Minh MachBurbank$559K
- Joseph HawkinsFresno$477K
- Michael BushBeverly Hills$380K
- Shawna WeislerBurbank$45K
- Ashiq PatelLancaster$32K
- Paul AzerBeverly Hills$25K
- Michael TranAnaheim$16K
- Samuel MayedaOrange$11K
- Daniel KaplanSan Leandro$8K
- Amy van BuiMission Viejo$8K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.